Show simple item record

dc.contributor.authorRobinson, Richard
dc.contributor.authorMarconi, Lorenzo
dc.contributor.authorMacPepple, Ekelechi
dc.contributor.authorHakenberg, Oliver W.
dc.contributor.authorWatkin, Nick
dc.contributor.authorYuan, Yuhong
dc.contributor.authorLam, Thomas
dc.contributor.authorMacLennan, Steven
dc.contributor.authorAdewuyi, Temitope E.
dc.contributor.authorCoscione, Alberto
dc.contributor.authorMinhas, Suks S.
dc.contributor.authorCompérat, Eva M.
dc.contributor.authorNecchi, Andrea
dc.date.accessioned2019-04-23T23:03:50Z
dc.date.available2019-04-23T23:03:50Z
dc.date.issued2018-07
dc.identifier.citationRobinson , R , Marconi , L , MacPepple , E , Hakenberg , O W , Watkin , N , Yuan , Y , Lam , T , MacLennan , S , Adewuyi , T E , Coscione , A , Minhas , S S , Compérat , E M & Necchi , A 2018 , ' Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer : A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel ' European Urology , vol. 74 , no. 1 , pp. 76-83 . https://doi.org/10.1016/j.eururo.2018.04.003en
dc.identifier.issn0302-2838
dc.identifier.otherPURE: 118587279
dc.identifier.otherPURE UUID: c73ebcd6-860e-45d6-9995-b5e712040898
dc.identifier.otherScopus: 85046134700
dc.identifier.urihttp://hdl.handle.net/2164/12211
dc.descriptionRichard Robinson certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Dr. Thomas Lam is a company consultant for and has received company speaker honoraria from Pfizer, GSK, Astellas, and Ipsen. Mr. Suks S. Minhas receives company speaker honorarium for Lilly and has received a fellowship/medical travel grant from American Medical systems Fellowship. Dr. Andrea Necchi is a company consultant for and has received company speaker honoraria from Bayer and Astra Zeneca, and has received a fellowship/medical travel grant from Pierre Fabre; he has been involved with trial participation for Roche, Merck Sharp & Dohme, BMS, and Novartis, as well as receiving grants/research supports from GlaxoSmithKline and Millenium. Oliver Hakenberg, Nick Watkin, Richard Robinson, Yuhong Yuan, Ekelechi MacPepple, Temitope E. Adewuyi, Steven MacLennan, Alberto Coscione, and Eva M. Compérat have nothing to declare.en
dc.format.extent8en
dc.language.isoeng
dc.relation.ispartofEuropean Urologyen
dc.rights© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectpenile canceren
dc.subjectadjuvant radiotherapyen
dc.subjectlymph nodesen
dc.subjectR Medicine (General)en
dc.subject.lccR1en
dc.titleRisks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer : A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panelen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen, Academic Urology Uniten
dc.contributor.institutionUniversity of Aberdeen, Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen, Other Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPostprinten
dc.identifier.doihttps://doi.org/10.1016/j.eururo.2018.04.003
dc.date.embargoedUntil24-04-20


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record